Programa del congreso
Resúmenes y datos de las sesiones para este congreso. Seleccione una fecha o ubicación para mostrar solo las sesiones en ese día o ubicación. Seleccione una sola sesión para obtener una vista detallada (con resúmenes y descargas, si están disponibles).
|
Resumen diario |
| Sesión | |
|
Ju-P2: Sesión de pósteres II Lugar: Zona pósteres | |
    | |
High-Throughput 3D Bioprinted Human Blood-Brain Barrier: Advancing In Vitro Modeling and Drug Screening for Neurodegenerative Diseases 1: Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; 2: Department of Electronic and Biomedical Engineering, University of Barcelona, Barcelona, Spain; 3: Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), ISCIII, Spain The blood–brain barrier (BBB) is essential for protecting the brain from harmful substances but also severely restricts central nervous system (CNS) drug delivery, contributing to the failure of nearly 80% of neurodegenerative disease (NDD) drug candidates in clinical trials. To address the need for more physiologically relevant preclinical models, we present a three-dimensional (3D) bioprinted human BBB platform using microvalve-based embedded 3D printing. Our low-viscosity bioink, formulated from natural polymers and brain microvascular endothelial cells (BMECs), recreates a biologically compatible microenvironment that more closely mimics the native BBB than synthetic alternatives. This strategy enables the reproducible fabrication of 3D ring-shaped scaffolds with high structural fidelity. Up to 48 constructs can be automatically printed within minutes while maintaining excellent cell integrity and viability, supported by precise droplet deposition and minimal shear stress. The platform further accommodates the incorporation of additional neural cell types, allowing systematic exploration of neurovascular interactions and dynamic crosstalk between cellular compartments. Its architecture also supports targeted delivery of drugs, nanoparticles, or imaging agents into the luminal channel, making it suitable for probing brain physiology, disease mechanisms, therapeutic efficacy and safety, and neuroimaging probe development. Collectively, these findings establish a robust, scalable, and cost-effective 3D bioprinted BBB model that holds significant promise for bridging the gap between preclinical studies and clinical translation in NDD drug development. | |